In March 2019, PainTherapeutics (NASDAQ:PTIE) announced that, effective immediately - better to reflect the shift in medical focus - the firm would be known as Cassava Sciences Inc (NASDAQ:SAVA). Previously located in California, Cassava Sciences is a biopharmaceutical company developing novel drugs originally based on technology licensed from the Albert Einstein College of Medicine: the firm having exclusive worldwide rights to patents covering low-dose opioid antagonist technology. With in-licensing over the years of technologies from others, the company?'s current lead drug candidate is REMOXY, a proprietary abuse-deterrent oral formulation of oxycodone for pain relief. The firm also develops FENROCK, a proprietary abuse-deterrent transdermal pain patch for pain relief; and PTI-125, a small molecule drug candidate to treat Alzheimer?s disease and other neurological disorders. The company is currently in a phase 2 testing of a drug candidate aimed at treating Alzheimer's, that does not seek to clear amyloid from the brain, but rather to stabilize a critical protein in the brain. Cassava Scences is also working to develop a biomarker/diagnostic to detect Alzheimer's using a simple blood test.